Analysts Cut Inspire Medical's Price Target Ahead of Q1 Earnings Report

Leerink analysts have revised Inspire Medical's (INSP) target price from $176 to $149, maintaining a Market Perform rating. The adjustment reflects recent financial disclosures and valuation insights. The average target price from 16 analysts is $216.68, indicating a 66.34% upside from the current price. Inspire Medical reported a 23% increase in revenue for Q1 2025 and provided full-year 2025 revenue guidance of $940 million to $955 million, representing 17% to 19% growth year-over-year.

Leerink analysts have revised their target price for Inspire Medical Systems Inc (INSP) from $176 to $149, while maintaining a Market Perform rating. This adjustment comes in anticipation of the company's upcoming quarterly earnings release. The update aligns with recent financial disclosures and new perspectives on valuation premiums within the industry.

The average target price from 16 analysts is $216.68, indicating a 66.34% upside from the current price of $130.26. The consensus recommendation from 20 brokerage firms is currently 2.1, indicating an "Outperform" status. GuruFocus estimates the GF Value for INSP in one year to be $359.65, suggesting a 176.1% upside from the current price.

Inspire Medical reported a 23% increase in revenue for Q1 2025, reaching $201.3 million. The company also provided full-year 2025 revenue guidance of $940 million to $955 million, representing 17% to 19% growth year-over-year. The full-year diluted net income guidance was raised to a range of $2.20 to $2.30 per share, reflecting confidence in future profitability.

However, the second quarter of 2025 is expected to be a transition period due to the launch of the Inspire V system, which may impact revenue growth. Revenue outside the US decreased by 6% year-over-year, indicating challenges in international markets. The company anticipates some inventory destocking and patient warehousing for the Inspire V system, which could affect short-term financial performance.

The revised target price and earnings expectations reflect a balanced view of Inspire Medical's performance and potential. Investors should closely monitor the company's earnings report for further insights.

References:
[1] https://www.gurufocus.com/news/2974954/inspire-medical-insp-target-price-cut-ahead-of-earnings-report-insp-stock-news
[2] https://www.tipranks.com/stocks/fold/forecast